Objectives To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy cohorts. Methods PCPTRC risks were calculated for 25,733 biopsies using prostate-specific antigen (PSA), digital rectal examination, family history, history of prior biopsy, and imputation for missing covariates. Predictions were evaluated using the areas underneath the receiver operating characteristic curves (AUC), discrimination slopes, chisquare tests of goodness of fit, and net benefit decision curves.
Introduction
The Prostate Cancer Prevention Trial (PCPT) Risk Calculator (PCPTRC) for prostate cancer was developed from 5,519 men from the placebo arm of the PCPT who underwent biopsy at or before the end of 7 years of annual prostate-specific antigen (PSA) and digital rectal exam (DRE) screening regardless of PSA or DRE indication [1] . Due to the required end-of-study biopsy, the PCPTRC is not subject to ascertainment bias, which results when only participants with clinical indications for biopsy are actually biopsied, while others are not and hence excluded from the study. However, there are several reasons why the PCPTRC may not be accurate when applied to other cohorts, including the use of a 6-core biopsy in place of more extended schemes and a majority of PSA values \3.0 ng/ml.
The purpose of the current study was to test the external validity of the PCPTRC for prostate cancer detection in ten European and US contemporary biopsy cohorts, some with more than 6-core biopsies performed and most with significant numbers of PSA values exceeding those in the PCPTRC cohort.
Methods
Data were included from ten European and US cohorts belonging to the Prostate Biopsy Collaborative Group (PBCG), where criteria for biopsy referral and sampling scheme have been previously summarized [2] . These included five screening cohorts from the European randomized study of screening for prostate cancer (ERSPC), three additional screening cohorts, San Antonio Biomarkers Of Risk of prostate cancer study (SABOR), Texas, US, ProtecT, United Kingdom, and Tyrol, Austria, and two US clinical cohorts, from Cleveland Clinic, Ohio, and Durham VA, North Carolina. All cohorts except for ERSPC Goeteborg and Rotterdam Rounds 1 included some patients who had been previously screened. All biopsies after a positive biopsy for prostate cancer were excluded from the analysis.
Clinical characteristics of each cohort were summarized in terms of median and range (age and PSA) and by numbers (percent) in each category (DRE, family history, African origin, prior negative biopsy, prostate cancer, and Gleason grade).
For each biopsy in the data set, the PCPTRC risk of a positive biopsy was computed, requiring PSA, DRE, family history of prostate cancer (father, brother or son ever diagnosed with prostate cancer), and history of a prior negative prostate biopsy. Within-cohort multiple imputation was used when the percentage of missing data for a risk factor in a cohort was less than 100%. The number of iterations was set to 20, and PCPTRC risks were computed as the average over five imputations of the missing risk factor [3, 4] . For cohorts with family history or DRE not recorded for any participants, single imputation of ''no family history'' and ''negative DRE'', respectively, were used following recommendation by the online PCPTRC.
Discrimination was calculated via receiver operating characteristics curves (ROC). Areas underneath the ROC curve (AUC) were calculated for PCPTRC risks and compared to those for PSA (provided by Kattan et al., unpublished manuscript) for the same cohort using U-statistics [5] . Calibration plots were computed by comparing observed proportions of cancer to mean PCPTRC risks by PCPTRC deciles observed in the cohort [6] . The HosmerLemeshow chi-square test was used to compare the same observed rates to predicted PCPTRC risks across the deciles. For this test, a P \ 0.05 indicates a poor agreement between predicted PCPTRC risks and actual observed risk. Net benefit curves were computed by calculating for each possible PCPTRC risk of a positive biopsy (p) ranging from 0 to 100%, sensitivity 9 %cancer -false-positive rate 9 %noncancer 9 [p/(1 -p)], and were assessed for their gain over the corresponding net benefit curves of referring no patients to biopsy (horizontal line at 0) or simply referring all patients to biopsy, %cancer -%non-cancer 9 [p/(1 -p)] [7] .
Results
Across the PBCG cohorts, age was fairly consistent with a median in the early sixties (Table 1) . Median PSA values ranged from 3.4 ng/ml in the SABOR cohort to 5.2 ng/ml in the Durham VA cohort, and rates of abnormal DRE, from a low of 10% in the Goeteborg Rounds 2-6 and Tyrol cohorts to a high of 31% in the Tarn cohort. Family history was only reported in half of the cohorts and those reported all fell at or below 11% except for SABOR at 29%. This was an artifact of selection bias for the SABOR cohort since its protocol included a family history substudy that offered biopsy to men with PSA less than 4 ng/ml and a positive family history. African origin was not reported in the European cohorts but could be presumed to be Table 1 Clinical characteristics of each cohort: age and PSA report median (range), the rest report number n Table 2 gives the external validation report for the PCPTRC in terms of discrimination, calibration, and clinical net benefit. AUCs of the PCPTRC ranged from a low of 56.2% in the Goeteborg Rounds 2-6 cohort to a high of 72.0% in the Goeteborg Round 1 cohort. While the AUC of the PCPTRC exceeded the AUC of PSA in all cohorts, it failed to be statistically significantly greater in 4 of the 10 cohorts: Rotterdam Rounds 2-3, Tarn, SABOR, and ProtecT, all screening rather than clinical cohorts.
Calibration plots of Fig. 1 indicate that the PCPTRC overestimated the risk of prostate cancer for men of low, medium and high risks for all of the ERSPC cohorts except for the Tarn section, where 95% confidence intervals of the observed risks overlapped with predicted PCPTRC risks.
The latter, however, could be attributed to the small sample size of the Tarn section (n = 298), which results in wider confidence bands and greater chance for overlap. For similar reasons, the PCPTRC appeared calibrated for the SABOR cohort (n = 392). The PCPTRC also overpredicted in risk ranges of practical relevance (below 50%) for the large Cleveland Clinic, Protect and Tyrol cohorts (Table 2) . However, for the Durham cohort (n = 2,419), which had the highest cancer prevalence (47%), the PCPTRC was calibrated across all risks. The HosmerLemeshow test rejected goodness of fit for all cohorts except for the SABOR cohort, but this test has the undesirable quality of being more likely to reject the null hypothesis of goodness of fit as the sample size increases so is not as objective a benchmark for calibration as the calibration plots.
The last column of Table 2 shows the range of risk thresholds for which the PCPTRC had higher clinical net benefit than the alternative strategies of biopsying all or no men. A risk threshold is the minimum risk at which a patient and clinician would opt for biopsy and varies between individuals due to personal preference. One reasonable threshold is 20%, suggesting that it would be worth conducting no more than 5 biopsies to find one cancer; a reasonable range of thresholds might be 15-30%. There was limited (ERSPC Tarn, Cleveland Clinic, ProtecT) to no clinical benefit at all (other four ERSPC cohorts) to using the PCPTRC to determine a subgroup of men to be biopsied compared to biopsying all of those meeting cohort-specific criteria for biopsy. For the remaining three cohorts, SABOR, Tyrol, and Austria, there was clinical benefit observed at reasonable risk ranges: 15-45%, 18-41%, and 25-100%, respectively ( Table 2) .
Discussion
Since its publication in 2006 and posting online for external validation, several single institutions or study reports of successful or failed validation of the PCPTRC have appeared leading to confusion as to whether the tool can be recommended in practice [8] [9] [10] [11] [12] [13] [14] . By examining the spectrum of answers obtained in a wide variety of cohorts using three complementary validation metrics, this report illuminates the inherent variability of results of external validation by cohort and chosen metric. This variation is not unique to the PCPTRC, but would rather extend to validation studies of all risk-prediction tools and the rapidly increasing numbers of investigations of new markers for enhancing prostate cancer, including the urine/blood markers PCA3, AMACR, MMP-2, and GSTP1/RASSF1A methylation status [15, 16] . Indeed, these results are a convincing demonstration that properties such as ''calibration [are] best seen not as a property of a prediction model, but of a joint property of a model and the particular cohort to which it is applied'' [17] . The AUC appears to be the most ubiquitous criterion implemented for validation in urologic research, but even in the absence of a calculator, the AUC for PSA itself evaluated across the ten cohorts of this study varied from no utility at all (AUC = 50.9%, Goeteborg Rounds 2-6) to fairly decent performance (AUC = 67.0%, Goeteborg Round 1) (data provided by Kattan). The AUC suffers an additional disadvantage by being influenced by selection of patients for inclusion based on PSA: including only patients with PSA exceeding 3 ng/ml will downwardly Fig. 1 Calibration plots for the PCPTRC showing average PCPTRC risks for men grouped by their PCPTRC risk value (x-axis) compared to the actual percentage of these groups, which were diagnosed with prostate cancer (y-axis). Perfect calibration would fall on the black diagonal line where predicted risks equal observed rates of prostate cancer influence the AUC. The PCPTRC amounts to a weighted average of PSA along with the dichotomous (yes versus no) risk factors of DRE, family history and prior biopsy, and as such its AUC typically tracks that of PSA in the same cohort. Accordingly, the AUC of the PCPTRC was also lowest in Goeteborg Rounds 2-6 (AUC = 56.2%) and highest in Goeteborg Round 1 (AUC = 72.0%). In these two cohorts along with four others, the AUC of the PCPTRC was statistically significantly higher than that of PSA. As noted by Kattan [18] , because of unmeasurable cohort differences, head-to-head comparisons of markers or calculators within cohorts and not across cohorts are key for unbiased comparisons.
Calibration plots confirmed an earlier PBCG observation that for most cohorts, the PCPTRC tends to give prostate cancer risk predictions that are too high, overestimating actual risks both in the PSA \4 ng/ml range, the range on which the PCPTRC was largely developed, and grossly overestimating outside this range [2] . The calibration plots revealed that the PCPTRC was better calibrated for cohorts with larger prevalences of cancer, in particular the Durham VA clinical cohort. A limitation of all results is that single imputation had to be performed for missing risk factors in several cohorts, and this would affect calibration. For example, family history was not recorded in five of the cohorts, so for these cohorts, the optimal value ''no family history'' was used for all participants. Unfortunately, calibration performed with the actual values of family history for men in these cohorts would be worse, since even with the favorable risk outcome imputed into the calculator, the PCPTRC still overestimated risks. Additionally, because the lowest PCPTRC risks observed in many of the cohorts fell near 30%, the current study provides no assessment of calibration of PCPTRC for lower risks that might be of greatest interest for decision-making concerning a biopsy.
Clinical net benefit is a more recently proposed validation metric that seeks to quantify the net benefit to a patient for using a particular decision rule to opt for a prostate biopsy, specifically, by choosing a threshold risk and deciding to undergo biopsy only if risk predicted by the decision rule exceeds this value. For each possible threshold, the net benefit of using the PCPTRC along with this threshold for referral to biopsy is assessed relative to just the rule of referring everyone in the cohort for biopsy. The five ERSPC cohorts had per protocol referral of men for biopsy for PSA exceeding 3 ng/ml (4 ng/ml in some sections at some years), and there was no observed benefit to using the PCPTRC for these men with primarily high risks to begin with. In contrast, net benefit of using the PCPTRC at thresholds 15-45% was observed in the SABOR cohort, a cohort with lower PSA values, and most similar in nature to the PCPT cohort as described above. Among the remaining cohorts, there was only limited net benefit at limited ranges of PCTPRC thresholds.
In sum, this study has shown that the PCPTRC may not be universally applicable, that in the population of men with elevated PSA (above 3.0 ng/ml) who would most seriously consider prostate biopsy; the PCTPRC may overestimate the risk of finding prostate cancer. This result could be due to that the PCPTRC was fit on a different population of men, primarily healthy men with PSA less than 3.0 ng/ml. The accuracy of the PCPTRC on such a healthy population of men is not ruled out by the current validation study, since no cohorts of this type were included. We are investigating a modification to the PCPTRC tailored to men more commonly referred to biopsy.
Findings of this study have implications for other riskprediction tools beyond the PCPTRC. It is typical in urologic research to declare definitive success or failure of a tool based on a single validation measure evaluated on data from a single institution. However, if validation is a function of both the model and the cohort being studied, there are two consequences. First, those proposing models must explore the properties of the model in different cohorts, and investigate the aspects of a cohort that affect model performance. Second, clinicians should be cautious in using a model unless it has been shown to provide added value, such as benefit, in a very similar population to the one in which it is being used clinically.
